PATENT APPLICATION **TRANSMITTAL**

Attorney Docket No. 48012

First Inventor or Application Identifier

Joan M. Robbins

RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE SKIN AND EX

DISEASES

₩ nly for nonprovisional applications under 37 CFR § 1.53(b))	Express Mail	Label No.	EL615230151US		>%	
APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.		ADDRES	Assistan	ent Application t Commissioner for Pa ton, D.C. 20231	100 109	
1. General Authorization Form & Fee Transmittal (Submit an original and a duplicate for fee processing)		6. Microfiche Computer Program (Appendix)				
2. Specification [Total Pages] 60 - Descriptive Title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D - Reference to Microfiche Appendix - Background of the Invention		7. Nucleotide and Amino Acid Sequence Submission (if applicable, all necessary)				
		 a. X b. X c. X Computer-Readable Copy (identical to computer copy) Statement verifying identity of above copies 				
- Brief Summary of the Invention		ACCOMPANYING APPLICATION PARTS				
Brief Description of the Drawings (if filed)Detailed Description		8. Ass	signment Papers (co	ver sheet & docum	ient(s))	
Claim(s)Abstract of the Disclosure			CFR 3.73(b) Statement en there is an assignee)	Power of A	ttorney	
3. X Drawing(s) (35 USC 113) [Total Sheets]	13	10. Eng	glish Translation Do	cument (if applica	able)	
4. Oath or Declaration [Total Pages]			rmation Disclosure ement (IDS)/PTO-1449	Copies of ID Citations	S	
a. Newly executed (original or copy)		12. Pre	eliminary Amendmer	nt		
b. Copy from a prior application (37 CFI (for continuation/divisional with Box 17 comp		13. X Ref	turn Receipt Postcar			
i. DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b) Incorporation By Reference (useable if box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered to be part of the disclosure		14. Small Entity Statement filed in prior application, Status still proper and desired				
			rtified Copy of Priori reign priority is claimed)	of Priority Document(s)		
		16. X Oth	er: <u>Certificate of Ex</u>	kpress Mail		
of the accompanying application and is hereby incorporated by reference therein.						
17. If a CONTINUING APPLICATION, check appropriate box and supply the requeste information below and in a preliminary amendment						
Continuation Divisional Continuation-In-Part (CIP) of prior Application No.:						
Prior application information: Examiner Group / Art Unit						
X Claims the benefit of Provisional Application No. 60/161,532, filed October 26, 1999						
CORRESPONDENCE ADDRESS						
David D. McMasters Seed Intellectual Property Law Group PLLC 701 Fifth Avenue, Suite 6300 Secure, Washington 98 10 1, 7092						

Seattle, Washington 98104-7092

Phone: (206) 622-4900 / Fax: (206) 682-6031

Respectfully submitted,

TYPED or PRINTED NAME SIGNATURE _

REGISTRATION NO. 33,963

Date 25, 2000

PATENT TRADEMARK OFFICE





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Joan M. Robbins and Richard Tritz

Filed

October 26, 2000

For

RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE SKIN AND EYE DISEASES

Docket No.

480124.407

Date

October 25, 2000

Box Patent Application Assistant Commissioner for Patents Washington, DC 20231

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

Assistant Commissioner for Patents:

I hereby certify that the enclosures listed below are being deposited with the United States Postal Service "EXPRESS MAIL Post Office to Addressee" service under 37 C.F.R. § 1.10, Mailing Label Certificate No. EL615230151US, on October 25, 2000, addressed to Box Patent Application, Assistant Commissioner for Patents, Washington, DC 20231.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC

Jeanette West

QXL:lma

Enclosures:

Diskette regarding Sequence Listing Postcard

Form PTO/SB/05

Specification, Claims, Abstract (60 pages) Declaration regarding Sequence Listing

Sequence Listing (980 pages)

13 Sheets of Drawings (Figures 1-14B)